Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Names New CFO as M&A Strategy Rolls Up Sleeves

SAN FRANCISCO, June 19 - Invitrogen has promoted C. Eric Winzer into the CFO position, the company said today.


Winzer, formerly vice president for finance, takes over from James Glynn, who will remain executive vice president and on the board of directors.


The shuffle is designed to give Glynn more time to focus on mergers and acquisitions, a "major strategy" of the company, an Invitrogen spokesperson told GenomeWeb.


Invitrogen has the cash to do it: At the end of the first quarter 2002, the company reported $694 million in cash and cash equivalents.


Winzer was CFO of Life Technologies prior to the company's acquisition by Invitrogen in 2000.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.